7AY1 Stock Overview
Develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Actinium Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.38 |
| 52 Week High | US$9.80 |
| 52 Week Low | US$1.30 |
| Beta | 0.15 |
| 11 Month Change | -16.89% |
| 3 Month Change | -21.38% |
| 1 Year Change | -65.43% |
| 33 Year Change | -78.72% |
| 5 Year Change | -78.05% |
| Change since IPO | -99.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7AY1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -12.3% | 0.8% | -1.3% |
| 1Y | -65.4% | -17.5% | 7.4% |
Return vs Industry: 7AY1 underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 7AY1 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 7AY1 volatility | |
|---|---|
| 7AY1 Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7AY1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7AY1's weekly volatility has decreased from 19% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 37 | Sandesh Seth | www.actiniumpharma.com |
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients.
Actinium Pharmaceuticals, Inc. Fundamentals Summary
| 7AY1 fundamental statistics | |
|---|---|
| Market cap | €44.04m |
| Earnings (TTM) | -€39.29m |
| Revenue (TTM) | €77.78k |
558.4x
P/S Ratio-1.1x
P/E RatioIs 7AY1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7AY1 income statement (TTM) | |
|---|---|
| Revenue | US$81.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$81.00k |
| Other Expenses | US$41.00m |
| Earnings | -US$40.91m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.31 |
| Gross Margin | 100.00% |
| Net Profit Margin | -50,512.35% |
| Debt/Equity Ratio | 0% |
How did 7AY1 perform over the long term?
See historical performance and comparison